Skip to main content

Advertisement

Log in

Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations

  • Original Article
  • Published:
Familial Cancer Aims and scope Submit manuscript

Abstract

The risks of cancers other than breast and ovarian amongst BRCA1 and BRCA2 mutation carriers are based on relatively few family based studies with the risk of specific cancers tested in population based samples of cancers from founder populations. We assessed risks of “other cancers” in 268 BRCA1 families and 222 BRCA2 families using a person years at risk analysis from 1975 to 2005. Cancer confirmations were overall higher than in previous family based studies at 64%. There was no overall increase in risk for BRCA1 carriers although oesophagus had a significant increased RR of 2.9 (95% CI 1.1–6.0) and stomach at 2.4 (95% CI 1.2–4.3), these were based mainly on unconfirmed cases. For BRCA2 increased risks for cancers of the pancreas (RR 4.1, 95% CI 1.9–7.8) and prostate (RR 6.3, 95% CI 4.3–9.0) and uveal melanoma (RR 99.4, 95% CI 11.1–359.8) were confirmed. Possible new associations with oesophagus (RR 4.1, 95% CI 1.9–7.8) and stomach (RR 2.7, 95% CI 1.3–4.8) were detected but these findings should be treated with caution due to lower confirmation rates. In contrast to previous research a higher risk of prostate cancer was found in males with mutations in the BRCA2 OCCR region. The present study strengthens the known links between BRCA2 and pancreatic and prostate cancer, but throws further doubt onto any association with BRCA1. New associations with upper gastro-intestinal malignancy need to be treated with caution and confirmed by large prospective studies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S et al (1994) A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266(5182):66–71

    Article  PubMed  CAS  Google Scholar 

  2. Wooster R, Bignell G, Lancaster J, Swift S, Seal S, Mangion J et al (1995) Identification of the breast cancer susceptibility gene BRCA2. Nature 378(6559):789–792

    Article  PubMed  CAS  Google Scholar 

  3. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The breast cancer linkage consortium. Am J Hum Genet 62(3):676–689

    Article  PubMed  CAS  Google Scholar 

  4. Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M et al (1997) The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 336(20):1401–1408

    Article  PubMed  CAS  Google Scholar 

  5. Warner E, Foulkes W, Goodwin P, Meschino W, Blondal J, Paterson C et al (1999) Prevalence and penetrance of BRCA1 and BRCA2 gene mutations in unselected Ashkenazi Jewish women with breast cancer. J Natl Cancer Inst 91(14):1241–1247

    Article  PubMed  CAS  Google Scholar 

  6. Hopper JL, Southey MC, Dite GS, Jolley DJ, Giles GG, McCredie MR et al (1999) Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian breast cancer family study. Cancer Epidemiol Biomarkers Prev 8(9):741–747

    PubMed  CAS  Google Scholar 

  7. Antoniou A, Pharoah PDP, Narod S, Risch HA, Eyfjord JE, Hopper J, Loman N, Olsson H, Johannsson O, Borg A, Pasini B, Radice P, Manoukian S, Eccles D, Tang N, Olah E, Anton-Culver H, Warner E, Lubinski J, Gronwald J, Gorski B, Tulinius H, Thorlacius S, Eerola H, Nevanlinna H, Syrjakoski K, Kallionemi O-P, Thompson D, Evans C, Peto J, Lalloo F, Evans DG, Easton DF (2005) Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies. J Med Genet 42(7):602–603

    Article  PubMed  CAS  Google Scholar 

  8. Chen S, Iversen ES, Friebel T, Finkelstein D, Weber BL, Eisen A, Peterson LE, Schildkraut JM, Isaacs C, Peshkin BN, Corio C, Leondaridis L, Tomlinson G, Dutson D, Kerber R, Amos CI, Strong LC, Berry DA, Euhus DM, Parmigiani G (2006) Characterization of BRCA1 and BRCA2 mutations in a large United States sample. J Clin Oncol 24(6):863–871

    Article  PubMed  CAS  Google Scholar 

  9. King MC, Marks JH, Mandell JB (2003) Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302(5645):643–646

    Article  PubMed  CAS  Google Scholar 

  10. Evans DG, Shenton A, Woodward E, Lalloo F, Howell A, Maher ER (2008) Penetrance estimates for BRCA1 and BRCA2 based on genetic testing in a clinical cancer genetics service setting. BMC Cancer 8(1):155

    Article  PubMed  Google Scholar 

  11. Easton DF, Steele L, Fields P, Ormiston W, Averill D, Daly PA et al (1997) Cancer risks in two large breast cancer families linked to BRCA2 on chromosome 13q12–13. Am J Hum Genet 61(1):120–128

    Article  PubMed  CAS  Google Scholar 

  12. The breast cancer linkage consortium (1999) Cancer risks in BRCA2 mutation carriers. The breast cancer linkage consortium. J Natl Cancer Inst 91(15):1310–1316

    Google Scholar 

  13. Thompson D, Easton DF (2002) Breast cancer linkage consortium. Cancer incidence in BRCA1 mutation carriers. J Natl Cancer Inst 94(18):1358–1365

    Article  PubMed  CAS  Google Scholar 

  14. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE (1994) Risks of cancer in BRCA1-mutation carriers. Breast cancer linkage consortium. Lancet 343(8899):692–695

    Article  PubMed  CAS  Google Scholar 

  15. van Asperen CJ, Brohet RM, Meijers-Heijboer EJ, Hoogerbrugge N, Verhoef S, Vasen HF, Ausems MG, Menko FH, Gomez Garcia EB, Klijn JG, Hogervorst FB, van Houwelingen JC, van’t Veer LJ, Rookus MA, van Leeuwen FE (2005) Netherlands collaborative group on hereditary breast cancer (HEBON). Cancer risks in BRCA2 families: estimates for sites other than breast and ovary. J Med Genet 42(9):711–719

    Article  PubMed  Google Scholar 

  16. Gruber SB, Petersen GM (2002) Cancer risks in BRCA1 carriers: time for the next generation of studies. J Natl Cancer Inst 94(18):1344–1345

    Article  PubMed  Google Scholar 

  17. Breslow NE, Day NE (1987) Statistical methods in cancer research vol II. the design and analysis of cohort studies (IARC Scientific Publication No 82). International Agency for Research on Cancer, Lyon

    Google Scholar 

  18. Liede A, Karlan BY, Narod SA (2004) Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol 22(4):735–742

    Article  PubMed  CAS  Google Scholar 

  19. Dite GS, Whittemore AS, Knight JA, John EM, Milne RL, Andrulis IL, Southey MC, McCredie MR, Giles GG, Miron A, Phipps AI, West DW, Hopper JL (2010) Increased cancer risks for relatives of very early-onset breast cancer cases with and without BRCA1 and BRCA2 mutations. Br J Cancer 103(7):1103–1108

    Article  PubMed  CAS  Google Scholar 

  20. Cybulski C, Górski B, Gronwald J, Huzarski T, Byrski T, Debniak T, Jakubowska A, Wokołorczyk D, Gliniewicz B, Sikorski A, Stawicka M, Godlewski D, Kwias Z, Antczak A, Krajka K, Lauer W, Sosnowski M, Sikorska-Radek P, Bar K, Klijer R, Romuald Z, Małkiewicz B, Borkowski A, Borkowski T, Szwiec M, Posmyk M, Narod SA, Lubiński J (2008) BRCA1 mutations and prostate cancer in Poland. Eur J Cancer Prev 17(1):62–66

    Article  PubMed  CAS  Google Scholar 

  21. Lawniczak M, Gawin A, Białek A, Lubiński J, Starzyńska T (2008) Is there any relationship between BRCA1 gene mutation and pancreatic cancer development? Pol Arch Med Wewn 118(11):645–649

    PubMed  CAS  Google Scholar 

  22. Ferrone CR, Levine DA, Tang LH, Allen PJ, Jarnagin W, Brennan MF, Offit K, Robson ME (2009) BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 27(3):433–438

    Article  PubMed  CAS  Google Scholar 

  23. Niell BL, Rennert G, Bonner JD, Almog R, Tomsho LP, Gruber SB (2004) BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst 96(1):15–21

    Article  PubMed  CAS  Google Scholar 

  24. Hearle N, Damato BE, Humphreys J, Wixey J, Green H, Stone J, Easton DF, Houlston RS (2003) Contribution of germline mutations in BRCA2, P16(INK4A), P14(ARF) and P15 to uveal melanoma. Invest Ophthalmol Vis Sci 44(2):458–462

    Article  PubMed  Google Scholar 

  25. Ginsburg OM, Kim-Sing C, Foulkes WD, Ghadirian P, Lynch HT, Sun P, Narod SA (2010) Hereditary breast cancer clinical study group. BRCA1 and BRCA2 families and the risk of skin cancer. Fam Cancer [Epub ahead of print]

  26. Douglas FS, O’Dair LCO, Robinson M, Evans DGR, Lynch SA (1999) The accuracy of diagnosis as reported by the proband in families with cancer: a retrospective study. J Med Genet 36:309–312

    PubMed  CAS  Google Scholar 

  27. Akbari MR, Malekzadeh R, Nasrollahzadeh D, Amanian D, Islami F, Li S, Zandvakili I, Shakeri R, Sotoudeh M, Aghcheli K, Salahi R, Pourshams A, Semnani S, Boffetta P, Dawsey SM, Ghadirian P, Narod SA (2008) Germline BRCA2 mutations and the risk of esophageal squamous cell carcinoma. Oncogene 27(9):1290–1296

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by the Genesis Breast Cancer Prevention Appeal. The department of Genetic Medicine in Manchester is supported by the NIHR Manchester Biomedical Research Centre.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to D. G. R. Evans.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 44 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moran, A., O’Hara, C., Khan, S. et al. Risk of cancer other than breast or ovarian in individuals with BRCA1 and BRCA2 mutations. Familial Cancer 11, 235–242 (2012). https://doi.org/10.1007/s10689-011-9506-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10689-011-9506-2

Keywords

Navigation